148 related articles for article (PubMed ID: 24870821)
1. Clinical trials: More trials, fewer tribulations.
Eisenstein M
Nature; 2014 May; 509(7502):S55-7. PubMed ID: 24870821
[No Abstract] [Full Text] [Related]
2. How I treat chemorefractory metastatic colorectal cancer.
Chu E
Clin Adv Hematol Oncol; 2018 May; 16(5):340-345. PubMed ID: 29851930
[No Abstract] [Full Text] [Related]
3. Challenges ahead for companion diagnostics.
Schmidt C
J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
[No Abstract] [Full Text] [Related]
4. More trials, fewer tribulations.
Eisenstein M
Sci Am; 2014 Jul; 311(1):S9-11. PubMed ID: 24974700
[No Abstract] [Full Text] [Related]
5. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
6. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
7. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
8. Does Chemotherapy Induce Metastases?
Chabner BA
Oncologist; 2018 Mar; 23(3):273-274. PubMed ID: 29523674
[TBL] [Abstract][Full Text] [Related]
9. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.
Kato S; Subbiah V; Kurzrock R
J Natl Compr Canc Netw; 2017 Jul; 15(7):863-866. PubMed ID: 28687573
[No Abstract] [Full Text] [Related]
10. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
11. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
[No Abstract] [Full Text] [Related]
12. Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.
Selaru P; Tang Y; Huang B; Polli A; Wilner KD; Donnelly E; Cohen DP
Clin Transl Sci; 2016 Apr; 9(2):63-73. PubMed ID: 26841346
[No Abstract] [Full Text] [Related]
13. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib.
Hickinson DM; Marshall GB; Beran GJ; Varella-Garcia M; Mills EA; South MC; Cassidy AM; Acheson KL; McWalter G; McCormack RM; Bunn PA; French T; Graham A; Holloway BR; Hirsch FR; Speake G
Clin Transl Sci; 2009 Jun; 2(3):183-92. PubMed ID: 20443891
[TBL] [Abstract][Full Text] [Related]
14. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Toyooka S; Uchida A; Shigematsu H; Soh J; Ogino A; Takata M; Kiura K; Ouchida M; Kosaka T; Aoe M; Mitsudomi T; Date H
J Thorac Oncol; 2007 Apr; 2(4):321-4. PubMed ID: 17409805
[TBL] [Abstract][Full Text] [Related]
15. [Molecular targeted drugs against ALK fusions].
Mano H
Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):3-7. PubMed ID: 21747201
[No Abstract] [Full Text] [Related]
16. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
17. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.
Baselga J
Ann Oncol; 2002 Jan; 13(1):8-9. PubMed ID: 11863116
[No Abstract] [Full Text] [Related]
18. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
19. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
[TBL] [Abstract][Full Text] [Related]
20. Researchers may use cancer cell lines to identify target populations prior to clinical trials.
Tuma RS
J Natl Cancer Inst; 2006 Jun; 98(12):810-1. PubMed ID: 16788154
[No Abstract] [Full Text] [Related]
[Next] [New Search]
